Calidi eliminates President role; approves 1-for-12 reverse stock split effective Aug 5, 2025

Calidi Biotherapeutics, Inc.

Calidi eliminated the President, Medical & Scientific Affairs position held by Dr. Boris Minev, effective July 29, 2025; CMO Dr. Guy Travis Clifton assumes duties.
Reverse stock split at 1-for-12 ratio; shares expected to begin trading on split-adjusted basis on NYSE American at market open August 5, 2025.
Stockholders approved the reverse split on July 9, 2025; Board approved ratio on July 11, 2025; new CUSIP is 320703 408.
Fractional shares will be rounded up to the nearest whole share; no action required for book-entry or street name holders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.